BMS-981164 is a humanized, tetravalent bispecific antibody designed to simultaneously target interleukin-4 receptor alpha (IL-4Rα) and interleukin-31 (IL-31). IL-4Rα is a critical component for both IL-4 and IL-13 signaling, driving Type 2 inflammation, while IL-31 plays a central role in inducing pruritus (itch). By dual blockade of these pathways, BMS-981164 inhibits the inflammatory cascade and alleviates itching symptoms. The antibody demonstrates high potency in researching chronic inflammatory skin diseases such as atopic dermatitis (AD) and offers superior pharmacological profiles compared to the combination of monospecific antibodies.